Pivotal role of plasminogen-activator inhibitor 1 in vascular disease

被引:61
|
作者
Agirbasli, M [1 ]
机构
[1] Marmara Univ, Med Ctr, Div Cardiol, Istanbul, Turkey
关键词
plasminogen-activator inhibitor 1; atherosclerosis; thrombosis;
D O I
10.1111/j.1742-1241.2005.00379.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fibrinolysis plays a crucial role in the development of vascular disease. The interface between the plasminogen activators and inhibitors determines the fibrinolytic potential of human blood. In addition to fibrin degradation, fibrinolytic system components modulate several complex biological events such as angiogenesis, tumorigenesis, arteriosclerosis and cellular migration. Recent experimental and clinical data indicated that PAI-1 as a novel vascular risk factor. In this concise review, we will examine the accumulating evidence suggesting that there is an intricate relationship between these systems which may provide new therapeutic strategies for prevention of vascular disease. (C) 2005 Blackwell Publishing Ltd.
引用
收藏
页码:102 / 106
页数:5
相关论文
共 50 条
  • [41] THE ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE CLEARANCE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY RAT HEPATOMA-CELLS
    CAMANI, C
    BACHMANN, F
    KRUITHOF, EKO
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (08) : 5770 - 5775
  • [42] TISSUE PLASMINOGEN-ACTIVATOR RELEASE AND PLASMINOGEN-ACTIVATOR INHIBITOR LEVELS IN CLINICAL SUBSETS OF CORONARY-ARTERY DISEASE
    MEYERS, DG
    HAIRE, WD
    SEARS, TD
    CLINICAL RESEARCH, 1989, 37 (04): : A902 - A902
  • [43] PLASMINOGEN-ACTIVATOR INHIBITOR-1(PAI-1) AND TISSUE-PLASMINOGEN ACTIVATOR PLASMINOGEN-ACTIVATOR INHIBITOR-1(TPA-PAI-1) IN IDDM - PROFILE BY COMPLICATIONS
    SUMINSKI, R
    DASILVA, S
    SMITH, M
    ERBEY, J
    DIABETES, 1994, 43 : A197 - A197
  • [44] Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease.
    Kohler, HP
    Grant, PJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (24): : 1792 - 1801
  • [45] PLASMINOGEN-ACTIVATOR INHIBITOR TYPE .1. IMMUNOHISTOCHEMICAL LOCALIZATION IN DISEASED VASCULAR TISSUE
    BRADY, ST
    ROBERTS, SA
    CINES, DB
    TOMASZEWSKI, JE
    BARNATHAN, ES
    ARTERIOSCLEROSIS, 1990, 10 (05): : A810 - A810
  • [46] HUMAN PLASMINOGEN-ACTIVATOR INHIBITOR-1 DEFICIENCY
    FAY, WP
    SHAPIRO, AD
    SHIH, JL
    SCHLEEF, RR
    GINSBURG, D
    CIRCULATION, 1992, 86 (04) : S12 - S12
  • [47] THE PHARMACOKINETICS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN THE RABBIT
    MAYER, EJ
    FUJITA, T
    GARDELL, SJ
    SHEBUSKI, RJ
    REILLY, CF
    BLOOD, 1990, 76 (08) : 1514 - 1520
  • [48] TISSUE-PLASMINOGEN ACTIVATOR, PLASMINOGEN-ACTIVATOR INHIBITOR AND RISK OF PERIPHERAL ARTERIAL-DISEASE
    SMITH, FB
    LEE, AJ
    RUMLEY, A
    FOWKES, FGR
    LOWE, GDO
    ATHEROSCLEROSIS, 1995, 115 (01) : 35 - 43
  • [49] THE ROLE OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN FAILURE OF THROMBOLYTIC THERAPY WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR
    HUBER, K
    BECKMANN, R
    RAUSCHA, F
    PROBST, P
    KAINDL, F
    BINDER, BR
    ZEITSCHRIFT FUR KARDIOLOGIE, 1993, 82 : 195 - 200
  • [50] CIRCADIAN FLUCTUATIONS OF TISSUE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 ANTIGENS IN VASOSPASTIC ANGINA
    SAKATA, K
    HOSHINO, T
    YOSHIDA, H
    ONO, N
    OHTANI, S
    YOKOYAMA, S
    MORI, N
    KABURAGI, T
    KURATA, C
    URANO, T
    TAKADA, Y
    TAKADA, A
    AMERICAN HEART JOURNAL, 1992, 124 (04) : 854 - 860